Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Kathryn Lurain, MDMPH, Ramya Ramaswami, MBBS,MPH, Anaida Widell, RN, Irene Ekwede, RN, Jomy George, PharmD, Maryalice Stetler-Stevenson, MD PhD, Mark Raffeld, MD, Constance M. Yuan, MD PhD, Joseph Ziegelbauer, PhD, Frank Maldarelli, MD PhD, William D. Figg, PharmD, Cody Peer, PhD, Seth M. Steinberg, PhD, Denise Whitby, Thomas S. Uldrick, MD MS, Robert Yarchoan, MD

Blood (2019) 134 (Supplement_1): 4096.

https://doi.org/10.1182/blood-2019-122070

Published: 2019

Journal Articles

Preclinical Activity of Brentuximab Vedotin (SGN-35) in Primary Effusion Lymphoma (PEL),

Shruti Bhatt, Brittany Ashlock, Yaso Natkunam, MD, PhD, Juan Carlos Ramos, MD, Enrique Mesri, PhD, Izidore S Lossos, MD

Blood (2011) 118 (21): 3728.

https://doi.org/10.1182/blood.V118.21.3728.3728

Published: 2011

Journal Articles

Clonally Related B-NHL Populations and Cell Lines Harbor Subsets with Significant Phenotypic and Functional Heterogeneity.

Sherry A. Wuensch, Randall M. Rossi, Richard Burack, Paul G. Rothberg, Craig T. Jordan, Faith M Young

Blood (2009) 114 (22): 1699.

https://doi.org/10.1182/blood.V114.22.1699.1699

Published: 2009

Journal Articles

Loss of Heterozygosity on Chromosome 6q14-q24 Confers Poor Outcome on Children and Adolescents with T-Cell Lymphoblastic Lymphoma.

Birgit Burkhardt, MD, Jochen Bruch, PhD, Franziska Mueller, Janina Salzburg, MD, Jochen Harbott, PhD, Alfred Reiter, MD

Blood (2005) 106 (11): 2809.

https://doi.org/10.1182/blood.V106.11.2809.2809

Published: 2005

Journal Articles

Proteinase-Activated Receptor 1, 3 Expression in Primary Human Carcinoma Cells.

Wan-Zhuo Xie, He Huang, Zhen Cai, Mao-Fang Lin, Frank Gieseler

Blood (2005) 106 (11): 4113.

https://doi.org/10.1182/blood.V106.11.4113.4113

Published: 2005

Journal Articles

Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene

AF Gazdar, HK Oie, IR Kirsch, GF Hollis

Blood (1986) 67 (6): 1542–1549.

https://doi.org/10.1182/blood.V67.6.1542.1542

Published: 1986

NARROW

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Preclinical Activity of Brentuximab Vedotin (SGN-35) in Primary Effusion Lymphoma (PEL),

Clonally Related B-NHL Populations and Cell Lines Harbor Subsets with Significant Phenotypic and Functional Heterogeneity.

Loss of Heterozygosity on Chromosome 6q14-q24 Confers Poor Outcome on Children and Adolescents with T-Cell Lymphoblastic Lymphoma.

Proteinase-Activated Receptor 1, 3 Expression in Primary Human Carcinoma Cells.

Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene

Email alerts

ASH Publications

American Society of Hematology

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Preclinical Activity of Brentuximab Vedotin (SGN-35) in Primary Effusion Lymphoma (PEL),

Clonally Related B-NHL Populations and Cell Lines Harbor Subsets with Significant Phenotypic and Functional Heterogeneity.

Loss of Heterozygosity on Chromosome 6q14-q24 Confers Poor Outcome on Children and Adolescents with T-Cell Lymphoblastic Lymphoma.

Proteinase-Activated Receptor 1, 3 Expression in Primary Human Carcinoma Cells.

Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only